Although allopurinol is the most widely prescribed first-line urate-lowering therapy (ULT) worldwide, its clinical use is accompanied by the risk of a rare but life-threatening adverse drug reaction: Allopurinol Hypersensitivity Syndrome (AHS). AHS is classified under Severe Cutaneous Adverse Reactions (SCARs), which include Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS). With a mortality rate of up to 20% to 30%, identifying at-risk patients and recognizing early warning signs is a critical priority for rheumatologists and primary care clinicians alike.
Clinical Presentation and Pathopathology of AHS
AHS is a systemic, T-cell-mediated hypersensitivity reaction. It is triggered not by allopurinol itself, but by its active metabolite, oxypurinol, which binds to specific human leukocyte antigen (HLA) proteins and initiates an immune response. AHS typically develops within the first 2 to 8 weeks of starting allopurinol therapy. The syndrome is defined by a triad of clinical features:
- Severe Cutaneous Eruption: This can range from an exfoliative maculopapular rash to widespread epidermal detachment and mucosal blistering characteristic of SJS/TEN.
- Systemic Involvement: High spikes in body temperature (fever) are common, along with multi-organ involvement, particularly acute kidney injury (interstitial nephritis) and acute hepatitis (elevated transaminases).
- Hematologic Abnormalities: Marked leukocytosis and eosinophilia (often > 10% of total white blood cell count) are classic hallmarks, indicating systemic immune activation.
Because the mortality rate of AHS is high, immediate cessation of allopurinol is mandatory if a patient develops any unexplained skin rash, hives, or fever during the first few months of therapy. Treatment requires hospitalization, supportive care (often in a burn unit for SJS/TEN), and systemic immunomodulating therapy, such as high-dose corticosteroids or cyclosporine.
The Genetic Link: HLA-B*5801 Allele
Scientific research has identified a strong genetic association between AHS and the HLA-B*5801 allele, a variant of the major histocompatibility complex (MHC) class I gene. Individuals carrying this allele have a significantly increased risk of developing AHS when exposed to allopurinol, with an odds ratio exceeding 100 in certain populations. The prevalence of the HLA-B*5801 allele varies across different ethnic backgrounds:
- High-Risk Populations: The allele is most common among individuals of Han Chinese, Thai, Korean, and African ancestry, with carriage rates ranging from 7% to over 15%.
- Lower-Risk Populations: In populations of European or Hispanic descent, the carriage rate is much lower, typically between 1% and 2%.
Based on this evidence, the 2020 American College of Rheumatology (ACR) guidelines strongly recommend screening for the HLA-B*5801 allele prior to initiating allopurinol in patients of Southeast Asian descent (e.g., Han Chinese, Korean, Thai) and in African American patients. If a patient tests positive for the HLA-B*5801 allele, allopurinol is contraindicated, and alternative urate-lowering therapies such as febuxostat or benzbromarone should be selected.
💡 💡 Clinical Pearl: HLA-B*5801 Screening Protocol
Do not initiate allopurinol in high-risk ethnic groups (Southeast Asian and African American patients) without checking their HLA-B*5801 status. If testing is positive, bypass allopurinol entirely and prescribe febuxostat, keeping in mind the necessary cardiovascular risk checks.
Prevention Strategies: Dosing and Titration
In addition to genetic screening, clinical studies have shown that the starting dose of allopurinol is an independent risk factor for AHS. The risk is elevated when allopurinol is started at high doses, especially in patients with pre-existing renal impairment. Therefore, the primary strategy to prevent AHS is to start allopurinol at a low dose (≤ 100 mg daily, and 50 mg daily in patients with CKD stage 3-5) and titrate the dose upward slowly. This gradual exposure allows the immune system to tolerate the drug, reducing the likelihood of a hypersensitivity reaction. Furthermore, regular blood tests during the initiation phase are essential to monitor kidney and liver function, as detailed in laboratory monitoring in gout.
💡 Frequently Asked Questions (FAQ)
Q1: What is the HLA-B*5801 test, and who needs it?
A1: It is a genetic blood test that detects a specific gene variant associated with a high risk of developing a life-threatening allergic reaction to allopurinol. It is strongly recommended for patients of Southeast Asian descent (Han Chinese, Korean, Thai) and African American patients before starting allopurinol.
Q2: What are the early signs of Allopurinol Hypersensitivity Syndrome (AHS)?
A2: The early signs typically appear within the first 8 weeks of starting allopurinol and include a skin rash, peeling skin, blisters in the mouth or eyes, high fever, and flu-like symptoms. If these occur, stop the medication immediately and seek emergency medical care.
Q3: If I test positive for the HLA-B*5801 gene, what other medications can I take?
A3: If you carry the gene, you should avoid allopurinol. Your doctor will prescribe an alternative medication to lower your uric acid, such as febuxostat or benzbromarone.
📚 References & Sources
- Hung, S. I., et al. (2005). HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proceedings of the National Academy of Sciences (PNAS), 102(11), 4134-4139.
- FitzGerald, J. D., et al. (2020). 2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis Care & Research, 72(6), 744-760.